General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Kadcyla (trastuzumab emtansine)
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Metastatic Breast Cancer
Last updated March 31, 2014
Xiaflex (collagenase clostridium histolyticum)
Status:
Negotiations were not pursued
Manufacturer:
Auxillium Pharmaceuticals Inc.
Indication:
Dupuytren's contracture with a palpable cord
Last updated March 18, 2014
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Advanced Non-Squamous Non-Small Cell Lung Cancer
Last updated February 28, 2014
Oralair (grass pollen allergen extract)
Status:
Concluded with an LOI
Manufacturer:
Paladin Labs Inc.
Indication:
Allergic Rhinitis
Last updated February 17, 2014
Status:
Negotiations were not pursued
Manufacturer:
Otsuka Canada Pharmaceutical Inc.
Indication:
Hyponatremia, non-hypovolemic
Last updated January 31, 2014
Status:
Negotiations were not pursued
Manufacturer:
Biogen Canada Inc.
Indication:
Multiple Sclerosis, improve walking disability
Last updated January 31, 2014
Adcetris (brentuximab vedotin)
Status:
Concluded with an LOI
Manufacturer:
Seattle Genetics Inc.
Indication:
Systemic Anaplastic Large Cell Lymphoma
Last updated January 31, 2014
Status:
Negotiations were not pursued
Manufacturer:
GlaxoSmithKline Inc.
Indication:
Systemic lupus erythematosus
Last updated January 31, 2014
Status:
Concluded with an LOI
Manufacturer:
Janssen Inc.
Indication:
Metastatic Castration-Resistant Prostate Cancer
Last updated January 23, 2014
Status:
Negotiations were not pursued
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Metastatic Colorectal Cancer
Last updated January 21, 2014